MedGene Therapeutics, Inc.

General Information

Company Name

Founded Year

2015

Location (Offices)

Gaithersburg, United States +1

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Health Care

Funding Stage

Seed

Social Media

MedGene Therapeutics, Inc. - Company Profile

MedGene Therapeutics, Inc. is a T cell therapy biotech start-up based in MD, USA, with a mission to improve lives through advanced scientific innovations. The company focuses on T cell immunotherapy for treating solid tumor cancers, harnessing the body's natural defense mechanism. Through the extraction, replication, and enrichment of a patient's active T cells, followed by reinfusion into the bloodstream, MedGene Therapeutics enhances the body's defenses against cancer. While T cell therapy has a long history, its efficacy in solid tumors has been limited until now.

MedGene Therapeutics has made significant strides by licensing PBL-T from NIH and developing RIV-8 in collaboration with Seoul National University. These are the result of years of dedicated research and represent the fundamental platform technologies for the company. Founded in 2015, the startup operates in the Biotechnology and Health Care industries. The latest milestone for MedGene Therapeutics is its $1.10M Seed Round investment secured on 25 June 2021. Notably, the investors for this round have not been disclosed yet.

Taxonomy: T cell therapy, biotech startup, immunotherapy, solid tumor cancers, PBL-T, RIV-8, collaboration with Seoul National University, ACT treatments, metastatic soft tissue sarcoma, metastatic follicular thyroid cancer, NIH patented technology, commercialization, cancer treatment, medical research, biopharmaceutical industry